Ovarian cancer is dominated by surgery and systemic therapy. As radiation oncologists, we’re expert consultants who step in at critical junctures: to clarify staging and risk, to advise on maintenance systemic strategies that shape recurrence patterns, and to deliver highly conformal radiation for palliation or carefully selected oligometastatic disease. Today we’ll cover surgical staging and cytoreduction goals, the modern systemic landscape (including PARP inhibitors and HRD), and radiation’s niche roles—palliative EBRT and SBRT for oligometastatic or oligoprogressive disease.

Ver todos los episodios